Valuation: Gan & Lee Pharmaceuticals.

Market Cap 40.07B 6B 5.44B 5.03B 4.54B 8.56B 566B 8.86B 60.44B 23.97B 302B 22.53B 22.05B 960B P/E 2026 *
28.3x
P/E 2027 * 24.7x
Enterprise Value 36.87B 5.52B 5.01B 4.63B 4.18B 7.87B 521B 8.15B 55.61B 22.05B 278B 20.73B 20.29B 883B EV / Sales 2026 *
7.4x
EV / Sales 2027 * 6.24x
Free-Float
57.94%
Yield 2026 *
0.36%
Yield 2027 * 0.4%
1 day-1.95%
1 week-5.70%
Current month-1.45%
1 month-2.15%
3 months-10.23%
6 months+18.71%
Current year-1.12%
1 week 67.03
Extreme 67.03000000
72.37
1 month 65.5
Extreme 65.5
73.73
Current year 51.51
Extreme 51.51
79.99
1 year 51.51
Extreme 51.51
79.99
3 years 32.1
Extreme 32.1
82.25
5 years 30.53
Extreme 30.53
82.25
10 years 30.53
Extreme 30.53
204.41
Manager TitleAgeSince
Chief Executive Officer 46 2025-05-29
Director of Finance/CFO 44 2026-03-08
Chief Tech/Sci/R&D Officer - 2026-03-08
Director TitleAgeSince
Director/Board Member 41 2025-11-16
Chairman 78 1998-06-16
Director/Board Member 49 2009-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 Sell

Director

-10,000 0.0019%
9/29/26 Sell

Company Secretary

-15,000 0.0028%
9/29/26 Sell

Chief Executive Officer

-5,000 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-1.95%-5.70%+0.09%+39.88% 6B
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.04%+1.46%+31.86%+79.02% 430B
Weighted average by Cap. +0.53%+3.25%+37.65%+96.42%

Financials

2026 *2027 *
Net sales 4.98B 747M 677M 626M 565M 1.06B 70.41B 1.1B 7.52B 2.98B 37.61B 2.8B 2.74B 119B 5.74B 860M 779M 721M 650M 1.23B 81.1B 1.27B 8.66B 3.43B 43.32B 3.23B 3.16B 138B
Net income 1.43B 214M 194M 180M 162M 305M 20.2B 316M 2.16B 855M 10.79B 804M 787M 34.25B 1.63B 244M 221M 204M 184M 347M 22.99B 360M 2.45B 973M 12.28B 915M 895M 38.98B
Net Debt -3.2B -480M -435M -402M -363M -684M -45.24B -708M -4.83B -1.92B -24.17B -1.8B -1.76B -76.71B -4.26B -638M -578M -534M -482M -909M -60.11B -941M -6.42B -2.55B -32.11B -2.39B -2.34B -102B
Projected Income Statement - Annual - Gan & Lee Pharmaceuticals.
Logo Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals is a China-based company primarily engaged in the research, development, production, and sales of insulin analogue active pharmaceutical ingredients and injectable formulations. The Company’s main products include glargine insulin injection, lispro insulin injection, mixed protamine zinc lispro insulin injection, aspart insulin injection, aspart 30 insulin injection, and mixed protamine human insulin injection. The Company is also engaged in the provision of medical device products, including reusable pen insulin injectors, non-reusable pen injectors, disposable injection pen needles, and disposable insulin pen needles. The Company distributes its products within the domestic market and to overseas markets.
Employees
5,309
Date Price Change Volume
26-11-13 CN¥67.31 -1.95% 4,971,804
26-11-12 CN¥68.65 -0.94% 4,379,273
26-11-11 CN¥69.30 -0.12% 3,830,225
26-11-10 CN¥69.38 -1.18% 4,176,122
26-11-09 CN¥70.21 -1.64% 4,034,175
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Gan & Lee Pharmaceuticals.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
67.31CNY
Average target price
83.50CNY
Spread / Average Target
+24.05%
  1. Stock Market
  2. Stocks
  3. 603087 Stock